Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Nov 23.

Published in final edited form as: Vaccine. 2009 Sep 26;27(50):7080–7086. doi: 10.1016/j.vaccine.2009.09.060

Similar to that described in Figure 2, the poly-functional CD4+ T cells at 2 weeks post the 4^th vaccination in trial participants were quantified by ICS assay. (a) For each participant with a positive response, the percentage of HIV-specific CD4+ T cells producing 1, 2, 3, or 4 cytokines is shown. Treatment group 1 is in red, group 5 in green, group 2 and 3 (blue) are combined since they both received 0.2mg of the EP-1043 vaccine. Group 4 is not shown because there no responses to the DNA vaccine. (b) The HIV-specific CD4+ T cells are further characterized by the specific cytokine or combination of cytokines produced. For each graph, the percentages plotted are relative to the HIV-specific CD4+ T cells producing 1, 2, or 3 cytokines.

Similar to that described in Figure 2, the poly-functional CD4+ T cells at 2 weeks post the 4^th vaccination in trial participants were quantified by ICS assay. (a) For each participant with a positive response, the percentage of HIV-specific CD4+ T cells producing 1, 2, 3, or 4 cytokines is shown. Treatment group 1 is in red, group 5 in green, group 2 and 3 (blue) are combined since they both received 0.2mg of the EP-1043 vaccine. Group 4 is not shown because there no responses to the DNA vaccine. (b) The HIV-specific CD4+ T cells are further characterized by the specific cytokine or combination of cytokines produced. For each graph, the percentages plotted are relative to the HIV-specific CD4+ T cells producing 1, 2, or 3 cytokines.